Healthcare utilization and costs in patients with benign prostatic hyperplasia： a population-based study

作     者：Shiu-Dong Chung Ya-Mei Tzeng Herng-Ching Lin Chao-Yuan Huang 

作者机构：Division of Urology Department of Surgery Far Eastern Memorial Hospital New Taipei City Taiwan China School of Medicine Fu-Jen Catholic University New Taipei City Taiwan China Sleep Research Center Taipei Medical University Hospital Taipei Taiwan China Graduate Institute of Life Science National Defense Medical Center Taipei Taiwan China Department of Urology National Taiwan University Hospital College of Medicine National Taiwan University Taipei Taiwan China School of Public Health Taipei Medical University Taipei Taiwan China 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2016年第18卷第6期

页      面：942-945页

核心收录：

学科分类：10[医学] 

主　　题：benign prostatic hyperplasia epidemiology health care utilization 

摘      要：This study aimed to investigate differences in healthcare service utilization between patients with and those without benign prostatic hyperplasia （BPH） using Taiwan＇s National Health Insurance population-based database. A total of 7413 patients with BPH and 7413 age-matched patients without BPH were included. The outcome variable was 1-year utilization of healthcare services Jncluding the number of outpatient visits, inpatient days, and the costs of outpatient and inpatient treatments. In addition, we separated healthcare services into urology services and nonurology services for analysis. We found that as to the utilization of outpatient urological services, patients with BPH had more outpatient services （7.84 vs 0.52, P 〈 0.001）, higher outpatient costs （US$372 vs US$34, P 〈 0.001）, a longer length of inpatient stay （0.55 vs 0.11, P 〈 0.001）, higher in-patients costs （US$149 vs US$32, P 〈 0.001）, and higher total costs （US$521 vs US$67, P 〈 0.001） than the comparison group. As for nonurological services, patients with BPH also had more outpatient services （49.11 vs 24.79, P〈 0.001）, higher outpatient costs （US$1794 vs US$1014, P〈 0.001）, a longer length of in-patient stay （3.72 vs 2.04, P〈 0.001）, higher inpatient costs （US$874 vs US$486, P〈 0.001）, and higher total costs （US$2668 vs US$1500, P 〈 0.001） compared to comparison patients. We also found that the average total cost was about 2-fold greater for patients with BPH than comparison patients. We concluded that patients with BPH had higher healthcare utilization than comparison patients without BPH.